This article is more than 5 years old. Information may no longer be current.
MitraClip shows promise in real-world setting at 1 year
Click Here to Manage Email Alerts
Percutaneous mitral valve repair with the MitraClip was safe and reasonably effective at 30 days and 1 year in a real-world setting, according to study results.
Researchers of the study examined 30-day and 1-year outcomes of percutaneous mitral valve repair with the MitraClip (Abbott Vascular) technique in 117 patients with grade ≥3+ mitral regurgitation (MR) who were at high risk for surgery. Patients with moderate-to-severe (3+) or severe (4+) MR were enrolled in the ongoing, prospective GRASP registry.
Eighty-nine patients (76%) presented with functional MR and 28 patients (24%) with organic MR. Acute device success defined as residual MR ≤2+ after clip implantation was seen in all patients. There was no procedural mortality.
Major adverse events occurred in four patients at 30 days (4.3%). By 1 year, deterioration to MR ≥3+ occurred in 25% of patients with degenerative MR and 7% of those with functional MR. No surgery for mitral valve dysfunction was required. Freedom from death, surgery for mitral valve dysfunction or grade ≥3+ MR was 96.4% at 30 days and 75.8% at 1 year.
No significant differences between patients with degenerative MR and those with functional MR were noted in freedom from death, surgery for mitral valve dysfunction or grade ≥3+ at 30 days and 1 year.
Despite the higher risk at baseline, this study had a higher procedural success rate and lower risk for major adverse events than previous studies, the researchers noted, likely because a specifically trained team did all of the procedures.
“An additional explanation is that functional MR, which was more commonly observed in this registry, is a condition easier to intervene on, as shown by the lower device implantation time compared with degenerative MR,” they wrote.
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts